Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 13/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.68 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.68 |
| ▸ | ADORA2B | P29275 | 4/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5040895 | 0.86 | ADORA2A (0.98) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL13084518 | 0.84 | ADORA2A (0.77) | ADORA2AADORA3ADORA2B | |
| SCHEMBL28774024 | 0.82 | ADORA2A (0.83) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL8373455 | 0.81 | ADORA2A (1.00) | ADORA2AADORA2B | |
| SCHEMBL7753712 | 0.81 | ADORA2A (1.00) | ADORA2AADORA2B | |
| SCHEMBL24652562 | 0.81 | ADORA2A (1.00) | ADORA2AADORA2B | |
| SCHEMBL278439 | 0.81 | ADORA2A (1.00) | ADORA2AADORA2B | |
| SCHEMBL489384 | 0.81 | ADORA2A (1.00) | ADORA2AADORA2B | |
| SCHEMBL22826758 | 0.81 | ADORA2A (1.00) | ADORA2AADORA2B | |
| SCHEMBL489378 | 0.81 | ADORA2A (1.00) | ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2002515885-A | — | — | 2002-05-28 | — | — | JP | claimed |
| EP-0880353-A4 | COMPOSITIONS AND METHODS FOR MODULATING MELANIN PRODUCTION | THERASYS INC (US) | 2001-04-18 | — | — | EP | claimed |
| US-5998423-A | IN SKIN OR HAIR; ADMINISTERING ADENOSINE RECEPTOR ANTAGONIST | THERASYS, INC. (US) | 1999-12-07 | — | — | US | claimed |
| EP-0880353-A1 | COMPOSITIONS AND METHODS FOR MODULATING MELANIN PRODUCTION | Therasys, Inc. (US) | 1998-12-02 | — | — | EP | claimed |
| WO-1998015276-A1 | COMPOSITIONS AND METHODS FOR MODULATING MELANIN PRODUCTION | THERASYS, INC. (US) | 1998-04-16 | — | — | WO | claimed |
| US-20070059269-A1 | Administration of 8-hexadecene-1,16-dicarboxylic acid for promoting cohesion of the epidermal horny layer | L'OREAL (FR) | 2007-03-15 | — | — | US | disclosed |
| EP-1754513-A2 | Use of 8-hexadecene-1,16-dicarboxylic acid as a care agent for promoting the horny layer cohesion | L'OREAL (FR) | 2007-02-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070059269-A1 | Administration of 8-hexadecene-1,16-dicarboxylic acid for promoting cohesion of the epidermal horny layer | DSG1, CUTA, DSC1 | ADORA2A 4168/4885ADORA3 4055/4885ADORA1 3229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.